Michael Chang | Ashok Ilankovan | Stephanie Pan | Patric Prado | Alyssa Rios Faculty Advisor: Professor Konofagou December 2, 2008

Design Problem: Spinal Muscular Atrophy (SMA) : a genetic disease that attacks the motor neurons and leads to muscle weakness and atrophy. Current evaluations are subjective, inaccurate, and insensitive. Clinicians need a robust, quantitative motion analysis system Design Brief: Our device will: work for different patient body types quantify intentional movements of the patient not place excessive weight on the patient’s arms maintain natural movement paths reduce friction maintain support of the patient’s arm We propose to develop a device to capture and analyze the majority of motions made by SMA patients DS1 + 3 DS5 Executive Summary Company Overview The Market Business Model Developmen t Plan DS6 Financial Plan Design Problem and Brief

Our Mission Design a clinical tool to quantitatively evaluate the motions of SMA patients Our Innovative Product An intuitive and consistently accurate, yet affordable 2D motion tracking system coupled with a frictionless platform Our Strategic Advantage Synergistic integration of currently available technologies Potentially rapid entry into untapped market DS1 + 3 DS5 Executive Summary Company Overview The Market Business Model Developmen t Plan DS6 Financial Plan Executive Summary & Company Overview

DS1 + 3 DS5 Executive Summary Company Overview The Market Business Model Developmen t Plan DS6 Financial Plan Prototype Design: OptEval 2D Figure 1. Forearm Model Figure 2. Full Arm Model

DS1 + 3 DS5 Executive Summary Company Overview The Market Business Model Developmen t Plan DS6 Financial Plan Optical Mini Mouse Kinimax $ 10 Polyurethane/Polyethylene Foam 4" Thick, 24" X 24" Sheet $ 60 Porous Air Medium Glasgow Awaiting Quotation Ball Transfer McMaster $ 5 Distance Sensor: 3-30cm Sharp $ 10 Prototype Design: OptEval 2D

DecJanFebMarchAprilMay Frictionless Platform 2-point Motion Capture 1 st Proto: Integrated System 1 st Proto: Integrated System 2 nd Proto: Independent System 2 nd Proto: Independent System Optimization / Output / Clinical Trials Optimization / Output / Clinical Trials Prototype Plan Testing Parts for Alternative 1 st Proto: Integrated System 1 st Proto: Integrated System Output Software Clinical Trials Development Plan: Short Term Contingency: DS1 + 3 DS5 Executive Summary Company Overview The Market Business Model Developmen t Plan DS6 Financial Plan

Selling to SMA Clinics / Clinical Trials / Feedback First Product Custom Components Home Product Protocols, Data Transfer Home Product Protocols, Data Transfer Selling to SMA Clinics Mid-2009 DS1 + 3 DS5 Executive Summary Company Overview The Market Business Model Developmen t Plan DS6 Financial Plan Development Plan: Long Term

The Market Approximately 25,000 to 55,000 SMA patients in the U.S., Europe, and Japan The Customer Clinics that treat SMA SMA patients go to clinics for regular checkups at least once a month During these checkups, a battery of tests is performed to thoroughly evaluate the patient’s condition, including many tests of patient mobility and strength. Many of these evaluations can be enhanced by our device The Market DS1 + 3 DS5 Executive Summary Company Overview The Market Business Model Developmen t Plan DS6 Financial Plan

Impact Doctors will have the ability to monitor more patients with higher accuracy than ever before. Patients and their families will have more meaningful feedback in terms of their progress and condition. Researchers will have the ability to acquire objective, reproducible data. Future At-home testing Expanded application for patients with other neuromuscular diseases and stroke-related Large, untapped market with great potential for further expansion DS1 + 3 DS5 Executive Summary Company Overview The Market Business Model Developmen t Plan DS6 Financial Plan The Market (cont.) complications.

Marketing In-hospital demonstrations and statistical data to show reliability and robustness Requires personnel to make appointments and travel to SMA clinics Limited advertising Possibly through SMA websites and related diseases Referral Advertising Offer of incentive, 10% off next purchase if referred other customers Business Model DS1 + 3 DS5 Executive Summary Company Overview The Market Business Model Developmen t Plan DS6 Financial Plan

Device Sale Cost: $1000 Includes: Installation Service Contract 1 Year: $ % Discount on Additional Service/Parts 2 Years: $250 5% Discount on Additional Service/Parts 3 Years: $350 10% Discount on Additional Service/Parts Business Model (cont.) DS1 + 3 DS5 Executive Summary Company Overview The Market Business Model Developmen t Plan DS6 Financial Plan

Continuous Revenue Disposable foam arm support Software: $20/month Online Storage Database Monthly Subscription Fee Fixed Expenditure Fixed Server Maintenance Business Model (cont.) DS1 + 3 DS5 Executive Summary Company Overview The Market Business Model Developmen t Plan DS6 Financial Plan

DS1 + 3 DS5 Executive Summary Company Overview The Market Business Model Developmen t Plan DS6 Financial Plan Years Sell to Clinics Clinical Trials Years Research & Development Years 4 & Beyond Continue to sell to clinics Expand to home market Break Even Price (10 3 Dollars) Break Even Analysis Time (Years)

Motivation: Clinicians need a robust and quantitative motion capture and analysis system Proposed Solution: OptEval 2D Market: SMA Patients Customers: Clinicians Development Plan: 1 st Prototype by mid st Product by end of 2009 Further expansion: Optimized for home use Summary

Acknowledgements Elisa Konofagou, PhD Assistant Professor of Biomed. Eng. Columbia University Petra Kaufmann, MD Assistant Professor of Neurology Associate Director, Pediatric MDA Neuromuscular Clinic Elizabeth Hillman, PhD Assistant Professor of Biomed. Eng. Columbia University Keith Yeager Senior Staff Associate, Lab Manager Columbia University Jacqueline Montes Clinical Coordinator, Physical Therapist Pediatric MDA Neuromuscular Clinic Viktor Gamarnik Columbia University Alumnus Benjamin Koo Columbia University Alumnus Barclay Morrison, PhD Associate Professor of Biomed. Eng. Columbia University

Questions?